15 November 2019 → 13 January 2024
Regional and community funding: Special Research Fund
Medical and health sciences
- Applied immunology
- Compound screening
Acute HIV-infection Broadly neutralizing antibodies Cytokines HIV-1
The potential of AcTakines (immunocytokines with reduced binding affinity to decrease systemic side-effects) will be explored as a strategy towards HIV-1 cure. Bispecific IFN-I and IL-1β AcTakines will be constructed, targeting both HIV-infected cells and immune effector cell. They will be tested in vitro on primary cells from early treated HIV+ individuals and in vivo in a humanized mouse model.